192 related articles for article (PubMed ID: 38059346)
1. Practical clinical guidelines and pharmacological treatment for attention-deficit hyperactivity disorder in Asia.
Kawabe K; Horiuchi F; Matsumoto Y; Inoue S; Okazawa M; Hosokawa R; Nakachi K; Soga J; Ueno SI
Neuropsychopharmacol Rep; 2024 Mar; 44(1):29-33. PubMed ID: 38059346
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials.
Cerrillo-Urbina AJ; García-Hermoso A; Pardo-Guijarro MJ; Sánchez-López M; Santos-Gómez JL; Martínez-Vizcaíno V
J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):494-507. PubMed ID: 29897263
[TBL] [Abstract][Full Text] [Related]
3. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
Martinez-Raga J; Knecht C; Szerman N; Martinez MI
CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.
Wigal SB
CNS Drugs; 2009; 23 Suppl 1():21-31. PubMed ID: 19621975
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants.
Childress A
Expert Opin Pharmacother; 2024 May; 25(7):853-866. PubMed ID: 38771653
[TBL] [Abstract][Full Text] [Related]
6. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
[TBL] [Abstract][Full Text] [Related]
8. Physician perceptions of the use of medications for attention deficit hyperactivity disorder.
Stockl KM; Hughes TE; Jarrar MA; Secnik K; Perwien AR
J Manag Care Pharm; 2003; 9(5):416-23. PubMed ID: 14613439
[TBL] [Abstract][Full Text] [Related]
9. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological management of attention-deficit hyperactivity disorder.
Reeves G; Schweitzer J
Expert Opin Pharmacother; 2004 Jun; 5(6):1313-20. PubMed ID: 15163276
[TBL] [Abstract][Full Text] [Related]
11. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
Huang YS; Tsai MH
CNS Drugs; 2011 Jul; 25(7):539-54. PubMed ID: 21699268
[TBL] [Abstract][Full Text] [Related]
13. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
Foy JM; Earls MF
Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
[TBL] [Abstract][Full Text] [Related]
14. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.
Steer C; Froelich J; Soutullo CA; Johnson M; Shaw M
CNS Drugs; 2012 Aug; 26(8):691-705. PubMed ID: 22762726
[TBL] [Abstract][Full Text] [Related]
15. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
May DE; Kratochvil CJ
Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
[TBL] [Abstract][Full Text] [Related]
16. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
[TBL] [Abstract][Full Text] [Related]
17. Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder.
Babinski DE; Waxmonsky JG; Waschbusch DA; Humphery H; Pelham WE
J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):250-257. PubMed ID: 27991835
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
Chan E; Fogler JM; Hammerness PG
JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland ST; Steeves TD; Pringsheim T
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
